WOM (World of Medicine) fails to reach sales goal in 2002
This article was originally published in Clinica
Executive Summary
World of Medicine (WOM), a company that manufactures products for minimally invasive surgery, including lasers and insufflation pump systems, experienced a difficult financial year in 2002, with sales rising barely 2% to E30.9m ($32.8m). The Ludwigsstadt, Germany-based company made a loss before interest and tax of E1.9m, compared with a profit of E0.6m for the previous year, putting the company in the red for the first time in six years. "We are not satisfied with this result, as our goals for 2002 were set much higher," said WOM's CEO, Peter Wiest.
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.